What is ApoB and why test it instead of LDL?

ApoB (apolipoprotein B) sits 1-per-particle on every cholesterol particle capable of entering an artery wall, so measuring it counts the particles directly. Two people with the same LDL can have very different particle counts, and risk follows the count. ApoB is a standard blood test, inexpensive, and usually covered; it is simply not on the default panel.

What is a lipoprotein(a) test and who should get one?

Lp(a) is an inherited cholesterol particle measured with a 1-time blood test. About 20% of adults have an elevated level and most do not know it. Anyone with a family history of early heart attack or stroke, and by current European guidance every adult at least once, should have it measured. Levels above roughly 125 nmol/L mark meaningfully elevated risk.

What blood pressure should I target for prevention?

For most adults with cardiovascular risk factors, the evidence supports getting below 130/80, measured properly at home rather than in a rushed office moment. Home averages beat office readings for predicting outcomes. A validated upper-arm cuff, back supported, feet on the floor, 2 readings morning and evening for a week gives you a trustworthy average.

Do I need a cardiologist for any of this?

Not for prevention at this stage. Risk stratification, advanced lipids, home BP protocols, statin decisions, and CAC ordering are squarely primary care work when the practice has time to do them. Cardiology earns its place when there are symptoms, an abnormal stress test or angiogram-level findings, or complex established disease.

Why set an ApoB target of 80 instead of just "lower is better"?

Lower is better is true for ApoB, but targets create decisions. Below 80 mg/dL is a well-supported threshold for people with risk factors short of established disease; below 60 is the more assertive goal used when disease is confirmed. Priya's CAC of 12 puts her in confirmed-but-early territory, so 80 now, with a planned reassessment toward 60 as her trend data accumulates.

Her CAC was only 12. Why treat at all?

Because a positive score at 47 means the process started years ago and has decades left to run. CAC predicts risk by decade of exposure: the same score is far more concerning at 47 than at 72. Early, low-burden disease is where treatment buys the most artery-years per year of therapy.

How does perimenopause fit into her picture?

Estrogen loss across the menopause transition typically raises LDL and ApoB and can raise blood pressure, so a woman's late 40s are often the moment a stable "borderline" pattern starts drifting upward. That is an argument for establishing baselines and targets now rather than discovering the drift at 55.

What is ApoB and why test it instead of LDL?

ApoB (apolipoprotein B) sits 1-per-particle on every cholesterol particle capable of entering an artery wall, so measuring it counts the particles directly. Two people with the same LDL can have very different particle counts, and risk follows the count. ApoB is a standard blood test, inexpensive, and usually covered; it is simply not on the default panel.

What is a lipoprotein(a) test and who should get one?

Lp(a) is an inherited cholesterol particle measured with a 1-time blood test. About 20% of adults have an elevated level and most do not know it. Anyone with a family history of early heart attack or stroke, and by current European guidance every adult at least once, should have it measured. Levels above roughly 125 nmol/L mark meaningfully elevated risk.

What blood pressure should I target for prevention?

For most adults with cardiovascular risk factors, the evidence supports getting below 130/80, measured properly at home rather than in a rushed office moment. Home averages beat office readings for predicting outcomes. A validated upper-arm cuff, back supported, feet on the floor, 2 readings morning and evening for a week gives you a trustworthy average.

Do I need a cardiologist for any of this?

Not for prevention at this stage. Risk stratification, advanced lipids, home BP protocols, statin decisions, and CAC ordering are squarely primary care work when the practice has time to do them. Cardiology earns its place when there are symptoms, an abnormal stress test or angiogram-level findings, or complex established disease.

Why set an ApoB target of 80 instead of just "lower is better"?

Lower is better is true for ApoB, but targets create decisions. Below 80 mg/dL is a well-supported threshold for people with risk factors short of established disease; below 60 is the more assertive goal used when disease is confirmed. Priya's CAC of 12 puts her in confirmed-but-early territory, so 80 now, with a planned reassessment toward 60 as her trend data accumulates.

Her CAC was only 12. Why treat at all?

Because a positive score at 47 means the process started years ago and has decades left to run. CAC predicts risk by decade of exposure: the same score is far more concerning at 47 than at 72. Early, low-burden disease is where treatment buys the most artery-years per year of therapy.

How does perimenopause fit into her picture?

Estrogen loss across the menopause transition typically raises LDL and ApoB and can raise blood pressure, so a woman's late 40s are often the moment a stable "borderline" pattern starts drifting upward. That is an argument for establishing baselines and targets now rather than discovering the drift at 55.

Borderline Cholesterol: How ApoB, Lp(a), and BP Change the Plan | A Patient Case

TL;DR30-second take

A 47-year-old with an LDL of 121 had been told to 'watch it and recheck in a year.' Three numbers her checkup never measured changed the plan: an ApoB of 108 (a true particle count in the risky range), an Lp(a) of 142 nmol/L (an inherited risk factor 1 in 5 people carry), and a home blood pressure averaging 133/84. With her father's heart attack at 60, her lifetime risk was far higher than the 10-year calculator suggested. The plan: drive ApoB down with diet, muscle, and a statin discussion, confirm plaque status with a coronary calcium scan, track home BP against a 130/80 target, and recheck in 12 weeks instead of 12 months.

A patient I will call Priya came to me at 47 with a folder of old lab results and a question her last 3 checkups had not answered.

Every year her LDL cholesterol came back somewhere between 115 and 125. Every year the note said some version of "borderline, continue lifestyle measures, recheck in a year." And every year she left with the same uneasy feeling, because her father had a heart attack at 60, and nobody seemed to be doing anything except watching.

She was not asking for drama. She was asking the right question: is "borderline" a diagnosis, or is it just an unfinished workup?

Why "borderline" is usually an unfinished workup

A standard cholesterol panel measures the weight of cholesterol in your blood. It does not measure the 2 things that decide most heart-attack risk: how many cholesterol-carrying particles are in circulation, and whether you inherited a particle type that standard panels never see.

For a person with a strong family history, stopping at LDL is stopping one layer short. So we ran the layer that matters:

ApoB came back at 108. ApoB counts risk-carrying particles directly, 1 protein per particle. Priya's count sat in the range where plaque builds steadily, even though her LDL looked only mildly elevated.
Lp(a) came back at 142 nmol/L. Lp(a) is a cholesterol particle you inherit, carried by about 1 in 5 adults, and it raises risk independent of everything else. It barely responds to diet or exercise. Her father had never had his measured; there is a decent chance this number is the family history.
Home blood pressure averaged 133/84. Her office readings had bounced between 126 and 138 for years, always explained away as nerves. Two weeks of morning and evening readings at her kitchen table settled the question: her pressure runs high, most days, all day.

None of these 3 numbers is dramatic on its own. Together, in a 47-year-old with a father who had a heart attack at 60, they describe a trajectory, and trajectories are where prevention does its best work.

Why the 10-year calculator underestimated her

Plug Priya into a standard 10-year risk calculator and she scores low, mostly because she is 47 and female. This is where a lot of prevention stalls out: the calculator says low, the visit ends, and the recheck lands in 12 months.

The problem is that the calculator answers a narrow question: what is the chance of a heart attack in the next 10 years? Priya is not planning to stop living at 57. Her lifetime risk, with an ApoB of 108, an Lp(a) of 142, a rising blood pressure, and her genetics, is a different number entirely. Plaque laid down in her 40s and 50s compounds like debt, and the earlier the exposure starts, the more it compounds.

Risk stratification in preventive primary care means asking the lifetime question while there is still time to change the answer.

What we did about it

Priya's plan came together in 1 long visit, and none of it required a cardiologist referral:

A coronary calcium (CAC) scan to see whether her arteries had started keeping score. At 47 with this profile, a CAC gives usable information: a score above 0 confirms the disease is active and makes treatment decisions easy; a 0 at her age is reassuring but does not erase the Lp(a), because soft plaque calcifies late. Hers came back at 12, low but not 0. The debate about whether her risk was theoretical ended there.
An ApoB target instead of an LDL target. We set hers below 80, the range supported for people with established risk factors, with the option to push lower if the picture worsens.
Food and muscle first, statin without stigma. She wanted to try 12 weeks of focused changes: more protein and fiber, less refined carbohydrate, 2 strength sessions a week. We agreed, with a clear deal: if ApoB stayed above target at the recheck, she would start a statin, because with her Lp(a), the modifiable risks have to work harder. It did, and she did, without drama.
A home blood pressure protocol against a 130/80 target. A validated cuff, seated morning and evening readings for 1 week each month, averaged. Hers settled at 131/83 after the first 12 weeks of training and sodium attention, close enough to hold medication in reserve and keep measuring.
A follow-up cadence that matches the stakes. Labs and a visit at 12 weeks, then every 6 months once stable. Not because anything is urgent, but because "recheck in a year" is how borderline numbers get to compound unwatched.

What about her Lp(a)?

You cannot lower Lp(a) meaningfully with lifestyle, and the medications that target it directly are still in trials. That sounds like bad news, but knowing the number changed everything about how we treat what she can control. A high Lp(a) is a reason to be earlier and firmer with ApoB and blood pressure, not a reason for despair. It also triggered a family conversation: her brother and her 19-year-old daughter each deserve a 1-time Lp(a) test of their own, because the trait runs in families.

What I want you to take from Priya's case

"Borderline" is not a diagnosis. It is a signal that the cheap, 1-time tests that settle the question have not been run yet. An advanced lipid panel with ApoB and Lp(a), 2 weeks of home blood pressure readings, and, when the picture warrants it, a calcium scan turn "watch and wait" into a plan with numbers, targets, and dates.

If your labs keep coming back borderline and your family history keeps nagging at you, that combination is worth 1 thorough look. This is the work executive-physical-depth prevention and healthspan medicine are built around, inside an ordinary primary care relationship.

Key Takeaways

"Borderline cholesterol" plus family history means the workup is unfinished. ApoB, a 1-time Lp(a), and 2 weeks of home blood pressure finish it, cheaply.
ApoB counts the particles that cause plaque; LDL only weighs their cargo. Risk follows the count.
Lp(a) is inherited, present in 1 in 5 adults, and invisible on standard panels. Knowing it changes how firmly you treat everything else, and it is a family conversation, not just a personal one.
10-year risk calculators can lull younger patients, women most of all. The lifetime question is the one prevention can still change.
Home blood pressure averages against a 130/80 target beat a nervous office reading every time.
A coronary calcium scan is a cheap tiebreaker when the treatment decision could go either way, with known blind spots for soft plaque.

Scientific References

Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287-1295.
Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A European Atherosclerosis Society Consensus Statement. Eur Heart J. 2022;43(39):3925-3946.
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13-e115.
Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary Calcium Score and Cardiovascular Risk. J Am Coll Cardiol. 2018;72(4):434-447.
SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-2116.
El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506-e532.

ApoB and Heart Health - the particle count that predicts heart attacks better than LDL
Lp(a): The Inherited Risk Standard Panels Miss - the 1-time test 1 in 5 adults would learn something from
Lp(a) and Cholesterol - why perfect-looking cholesterol can still carry high risk
The Heart Attack We Caught Seven Years Early - the higher-risk version of this same story
Advanced Lipid Testing in Philadelphia - the panel this case rests on
Primary Care Physician in Philadelphia - prevention with this depth, inside an everyday care relationship

Fishtown Medicine | Cardiovascular risk

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

A CAC scan is most useful when the decision is truly uncertain: borderline lipids, mixed family history, a patient hesitant about medication. A score above 0 confirms active disease and usually settles the statin question. In younger patients or those with high Lp(a), a 0 is encouraging but not a free pass, because early soft plaque has not calcified yet. The scan costs around $75 to $150 in Philadelphia and takes minutes.

Deep-Dive Questions

A coronary CT angiogram (with or without AI plaque analysis) shows soft plaque a CAC misses and quantifies total burden, and it is the right test when symptoms or a high-risk profile demand certainty. For an asymptomatic patient whose decision hinged on "is disease present at all," the CAC answered the question at a fraction of the cost and radiation. If her numbers had argued for treatment while a 0 CAC argued against, a CTA would have been the tiebreaker.

Ready when you are